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PSY30
COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES 
VERSUS NO TREATMENT FOR MORBID OBESITY
Pasricha A, Blackhouse G, Goeree R, Tarride JE, O’Reilly D
PATH Research Institute, McMaster University, Hamilton, ON, Canada
OBJECTIVES: Obesity is a global epidemic and obesity-related comorbidities pose 
health risks alongside placing ﬁnancial burden on the health care system. Bariatric 
surgery has been shown to reduce weight, improve quality of life, and reduce mor-
bidity for morbidly obese individuals. The objectives of this evaluation are to assess 
the cost-effectiveness and cost-utility of bariatric surgery (gastric bypass (GB) and 
laparoscopic adjustable gastric banding (LAGB) procedures) versus no treatment for 
morbidly obese patients (body mass index ≥40 kg/m2). METHODS: A combined 
(decision tree and Markov) model was developed to compare the costs and outcomes 
of bariatric surgery with no treatment for morbid obesity over a 15-year time 
horizon. This evaluation was conducted from the perspective of the Ontario Ministry 
of Health and Long-Term Care. Data on BMI reduction, post-operative complications 
and mortality, costs of disease management, and health-related quality of life were 
used based on a literature review of national and international sources. Univariate 
and probabilistic sensitivity analyses were conducted. RESULTS: In the base case 
analysis, GB dominated LAGB and no treatment (cheaper and more effective in 
terms of life-years (LYs) gained and quality adjusted life-years (QALYs) gained). 
Univariate and probabilistic sensitivity analyses varying important model parameters 
such as treatment costs, probability of complications, and utility estimates did not 
impact this conclusion showing that the economic model is robust in nature. CON-
CLUSIONS: This evaluation showed that gastric bypass is the cheapest and most 
effective strategy for morbidly obese individuals in terms of cost per LY gained and 
cost per QALY gained.
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CLINICAL-ECONOMIC EVALUATION OF AZACITIDINE VERSUS 
DECITABINE FOR TREATING PATIENTS WITH MYELODYSPLASTIC 
SYNDROMES (MDS)
Miller JD1, Fenaux P2, Beach CL3, Gidwani R1, Khan ZM4
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OBJECTIVES: Azacitidine and decitabine are used to treat patients with myelodys-
plastic syndromes (MDS). We sought to determine their cost-effectiveness. 
METHODS: We developed a Markov process model (1-month cycles) to track 
hypothetical cohorts of MDS patients treated with azacitidine or decitabine over 2 
years. Model structure and parameters were derived from published literature, 
product labels, clinical trial data, and drug and medical services cost databases. Four 
health states were modeled: 1) MDS with transfusion dependence; 2) MDS with 
transfusion independence; 3) progression to acute myelogenous leukemia (AML); 
and 4) death. Cost-effectiveness was measured incrementally as: 1) cost per quality-
adjusted life year (QALY); 2) cost per month of transfusion independence; and 3) 
cost per case of AML progression avoided. The model used a third-party payer 
perspective with 2009 US costs. One-way sensitivity analyses were performed on 
key model parameters. RESULTS: The total number of QALYs (per 1000 patients) 
attained by azacitidine-treated patients exceeded those attained by decitabine-treated 
patients (1041 vs. 870). The total number of patient months with transfusion inde-
pendence was higher for azacitidine vs. decitabine (8328 vs. 6224). More azacitidine-
treated patients avoided progression to AML compared to decitabine-treated patients 
(509 vs. 285). Total per-patient costs for azacitidine were lower than for decitabine 
($150,322 vs. $166,212). Overall, treating a patient with azacitidine cost $15,890 
less than treating a patient with decitabine, and confers 0.171 additional QALYs. 
CONCLUSIONS: These ﬁndings demonstrate that azacitidine costs less than 
decitabine and provides greater clinical beneﬁt across key outcomes of interest. These 
results accentuate the role of azacitidine as a major asset in providing cost-effective 
care for MDS patients.
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COST-EFFECT ANALYSIS OF THE USE OF POSACONAZOLE FOR 
PROPHYLAXIS OF INVASIVE MYCOSES COMPARED TO FLUCONAZOLE 
AND ITRACONAZOLE IN PATIENTS WITH PRONOUNCED 
NEUTROPENIA
Kolbin AS1, Klimko N2, Koroleva O1
1Saint -Petersburg State University, Saint Petersburg, Russia, 2Saint—Petersburg Medical 
Academy of Postgraduate Education, Saint Petersburg, Russia
OBJECTIVES: It was the clinical economic study comparing posaconazole and ﬂuco-
nazole or itraconazole for primary prophylaxis of invasive mycoses (IM) in patients 
with pronounced neutropenia in Russian economic circumstances using methods of 
mathematic modeling METHODS: Overall cost was calculated, including the cost of 
prophylaxis and treatment of IM and number of life-years saved for each group 
patients. To evaluate the degree of inaccuracy of the results, sensitivity analyses were 
performed. It was shown that the mean value of IM treatment costs (calculated as the 
mean of the costs of voriconazole, caspufungine, and lipid amphotericin B) in the 
posaconazole group was lower compared to the group of ﬂuconazole/itraconazole. 
RESULTS: It was found that the difference was 0.94 with the less cost-requiring tactics 
of posaconazoole use. When the cost structure was studied in details it was shown 
that the group receiving posaconazole for prophylaxis had higher expenditures than 
the group taking ﬂuconazole/itraconazole (12.9 times difference), due to higher 
posaconazole price. In the treatment of IM overall expenditures in the group of 
posaconazole were lower compared to those in the group of ﬂuconazole/itraconazole 
(2.2 times difference), due to decreased risk of IM development in prophylactic use 
of posaconazole. The analysis of the main scenario demonstrates that the regimen of 
posaconazole use for prophylaxis was less expensive and more effective (dominating) 
compared to that with ﬂuconasole/itraconazole. Alternative scenario analysis, where 
IM and mortality rates were equal in both groups of prevention, showed dominating 
character of posaconazole prophylaxis strategy. One-sided sensitivity analysis demon-
strated that the rate of IM development when posaconazole was used for prophylaxis 
had more inﬂuence on incremental cost-effectiveness ratio, than the changes due to 
costs for antifungals purchase. CONCLUSIONS: Posaconazole prescription was eco-
nomically beneﬁcial compared to ﬂuconazole/itraconazole for prophylaxis of IM in 
the studied patient population.
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OPIOID USE AND COSTS IN PATIENTS WITH PAINFUL DIABETIC 
PERIPHERAL NEUROPATHY TREATED WITH PREGABALIN OR 
STANDARD-OF-CARE
Joshi AV1, Mardekian J2, Zlateva G1, Harnett J2
1Pﬁzer Inc., New York, NY, USA, 2Pﬁzer, New York, NY, USA
OBJECTIVES: To evaluate opioid use and medical services utilization and associated 
costs among patients with painful diabetic peripheral neuropathy (pDPN) who initi-
ated treatment with pregabalin (Pgb) versus standard of care (SOC) treatments. 
METHODS: Retrospective cohort analysis using the Thomson MedStat MarketScan 
commercial and Medicare supplemental insurance database (2005–2007) to identify 
patients prescribed Pgb or SOC (venlafaxine, duloxetine, gabapentin, tricyclic antide-
pressants) during 2006 subsequent to a diagnosis of DPN (ICD-9-CM codes 250.6x 
or 357.2x). Patients initiated on Pgb were propensity-score matched (1:1) with SOC 
patients on demographics, Charlson comorbidity score, and prior medication, inpa-
tient, and outpatient costs. Time-to-opioid prescription was assessed using a Cox-
Proportional hazards model and the proportion of patients dispensed opioids, number 
of opioid prescriptions, number of days of opioid therapy, and opioid, overall prescrip-
tion, and total medial service utilization costs in the 12-month post-index period were 
compared (paired t-tests) between Pgb and SOC. RESULTS: A total of 2,000 patients 
were evaluated (Pgb = 1000, SOC = 1000). 54% were male in both groups, with mean 
ages of 64.0 ± 11.2 years (Pgb) and 63.6 ± 11.9 years (SOC) and no difference in 
Charlson Comorbidity Index scores (Pgb:3.7 ± 1.6, SOC:3.7 ± 1.6). The proportion 
of patients prescribed opioids during the 1-year post-index period was similar between 
groups (41% for Pgb vs. 38% for SOC; P = 0.16). The time-to-ﬁrst opioid prescription 
was 148.5 ± 104.4 days versus 143.7 ± 101.7 days (P = 0.58) in the Pgb and SOC 
cohorts respectively, among opioid users. Total opioid-related prescription costs per 
patient were $21 ± $79 versus $23 ± $122 (P = 0.16) and overall prescription costs 
per patient were $5471 ± $3916 versus $5271 ± $4172 (p = 0.36) for Pgb and SOC, 
respectively. Total medical service utilization costs were $18,277 ± $33,299 for Pgb 
versus $19,639 ± $33,657 for SOC (p = 0.40). CONCLUSIONS: pDPN patients 
initiating Pgb experienced similar opioid use, and did not show differences in opioid, 
overall prescription and total medical resource utilization costs, compared with the 
SOC cohort.
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OBESITY AND HEALTH CARE COSTS AND UTILIZATION IN THE 
VETERAN AFFAIRS POPULATION
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OBJECTIVES: The escalating burden of obesity is of concern to patients, health care 
professionals, and policy makers. Health care costs and utilization over an eight-year 
time period was examined in overweight and obese individuals compared to normal 
weight individuals within the Veterans Affairs (VA) population. METHODS: This is 
a retrospective cohort study of medical and pharmacy records from the VA databases 
between 2000–2007. Cohorts were stratiﬁed based on age and BMI (kg/m2) at base-
line. Costs included total, pharmacy, inpatient, and outpatient costs. Utilization 
included inpatient stays and outpatient records. Repeated measures ANCOVA was 
used to assess the impact of longitudinal repeated costs over time between groups. 
Multiple and Poisson regressions were used to analyze total costs and utilization over 
the entire period. RESULTS: A total of 71,675 veterans were included. There were 
statistically signiﬁcant differences in all costs between BMI groups (p < 0.0001). Over 
the entire time period, compared to normal weight individuals, total adjusted costs 
were signiﬁcantly less for overweight and obese individuals (p < 0.0001) but no there 
was no signiﬁcant difference with severely obese individuals. Average pharmacy and 
outpatient costs per year for overweight, obese, and severely obese individuals were 
on higher than normal weight individuals (p < 0.0001). Over the entire time period, 
adjusted pharmacy costs were $643.61, $1110.03, and $1960.38 higher and outpa-
tient costs were $1021.91, $1651.29, and $2086.46 higher for overweight, obese, and 
severely obese individuals, respectively, compared to normal weight individuals (p < 
0.0001). However, average inpatient costs and stays per year were higher for normal 
weight individuals compared to other weight groups (p < 0.0001). CONCLUSIONS: 
It is unclear why inpatient costs are higher in normal weight individuals than other 
weight groups in the Veterans population. However, obesity has a signiﬁcant impact 
on medical and pharmacy cost and utilization and more emphasis should be placed 
in managing weight gain.
